Amid the ongoing global financial strains and a high interest rate environment, bioventures in South Korea are increasingly opting to raise funds through rights offerings, despite concerns over share dilutions and to push ahead with clinical trials and cover other operating costs.
Korean Biotechs Rush To Rights Offerings To Raise R&D Funds
Large VC Financing Still Limited
Listed Korean bioventures are increasingly opting for rights offerings in a high interest rate environment, while unlisted firms are turning more to smaller-scale VC financings.
